The low participation rate (35.35%) in our study will not allow us to draw conclusions on current clinical practices in primary prophylaxis of NF with G-CSF in cancer centers in Morocco (the place of G-CSF in our practices, the modalities of use of G-CSF, the real challenges limiting their prescription). Here, CSF3 is linked to cancer.